Unal Murat, Sevim Serhan, Doğu Okan, Vayisoğlu Yusuf, Kanik Arzu
Department of Otorhinolaryngology, Mersin University School of Medicine, Mersin, Turkey.
Acta Otolaryngol. 2003 Dec;123(9):1060-3. doi: 10.1080/00016480310000755.
To investigate the possible beneficial effects of botulinum toxin type A (BTX-A) on nasal symptoms in patients with allergic rhinitis (AR).
Thirty-four patients (21 females, 13 males; mean age 28 years) were included in the study. AR was diagnosed by means of history, clinical examination and skin prick test. Patients were randomly divided into 3 subgroups a follows: in Group A, 20 units of BTX-A was injected into each nasal cavity (total 40 units); in Group B, 30 units of BTX-A was injected into each nasal cavity (total 60 units); and in Group C, 2 ml of isotonic saline was injected as placebo. The symptoms of AR (rhinorrhea, nasal obstruction, sneezing, itching) were scored by the patient on a six-point scale (from 0 to 5). All of the patients were followed up at Weeks 1, 2, 4, 6 and 8; at each visit an anterior rhinoscopic examination was done and symptom scores were recorded.
There was no statistically significant difference between Groups A and B in terms of average symptom scores. Rhinorrhea, nasal obstruction and sneezing scores in Groups A and B were significantly better than those in Group C at all time points. Although itching scores were significantly lower at Weeks 1 and 2, there was no difference in the Week 4, 6 and 8 scores in Groups A and B. When total symptom scores were evaluated, the results for Groups A and B were similar but significantly better than those for Group C.
In selected cases, injection of 40 units of BTX-A into the turbinates, as a single agent, may help the symptomatic control of AR for up to 8 weeks.
探讨A型肉毒毒素（BTX-A）对变应性鼻炎（AR）患者鼻部症状可能的有益作用。
34例患者（21例女性，13例男性；平均年龄28岁）纳入本研究。通过病史、临床检查和皮肤点刺试验诊断AR。患者随机分为3个亚组如下：A组，每侧鼻腔注射20单位BTX-A（共40单位）；B组，每侧鼻腔注射30单位BTX-A（共60单位）；C组，注射2 ml等渗盐水作为安慰剂。AR症状（鼻流涕、鼻塞、打喷嚏、瘙痒）由患者采用六点量表（从0至5）评分。所有患者在第1、2、4、6和8周进行随访；每次随访时进行前鼻镜检查并记录症状评分。
A组和B组的平均症状评分在统计学上无显著差异。A组和B组在所有时间点的鼻流涕、鼻塞和打喷嚏评分均显著优于C组。虽然在第1周和第2周瘙痒评分显著较低，但A组和B组在第4、6和8周的评分无差异。评估总症状评分时，A组和B组的结果相似，但显著优于C组。
在选定病例中，作为单一药物向鼻甲注射40单位BTX-A可有助于AR症状控制长达8周。
